Table 2.
Effects of glibenclamide and the selected compounds on fasting blood glucose levels of normal, diabetic control, and diabetic treated rats.
| Group | Fasting Blood Glucose Level (mg/dL) | ||||
|---|---|---|---|---|---|
| Week 0 | Week 1 | Week 2 | Week 3 | Week 4 | |
| Normal control | 73.80 ± 4.50 | 75.60 ± 7.20 | 72.00 ± 6.30 | 72.00 ± 5.40 | 81.00 ± 2.16 |
| Diabetic control | 320.40 ± 20.52 | 401.40 ± 22.50 | 428.40 ± 50.40 | 433.80 ± 39.06 | 446.40 ± 31.68 |
| Glibenclamide (10 mg/kg) | 338.40 ± 16.38 | 271.80 ± 18.36 * | 183.60 ± 11.70 * | 216.00 ± 9.72 * | 203.40 ± 13.50 * |
| Compound 1 (100 mg/kg) | 342.00 ± 19.08 | 405.00 ± 17.46 | 392.40 ± 13.32 | 379.80 ± 19.44 | 396.00 ± 16.92 |
| Compound 10 (100 mg/kg) | 320.40 ± 12.96 | 270.00 ± 16.74 * | 286.20 ± 18.90 | 234.00 ± 14.58 * | 225.00 ± 11.70 * |
| Compound 11 (100 mg/kg) | 318.60 ± 17.64 | 365.40 ± 20.34 | 352.80 ± 27.36 | 324.00 ± 23.04 | 351.00 ± 26.64 |
| Compound 12 (100 mg/kg) | 325.80 ± 14.58 | 392.40 ± 36.54 | 379.80 ± 30.60 | 408.60 ± 20.52 | 432.00 ± 28.26 |
The data reported represent the means (n = 6) ± SD; * Mean values that are significantly different from diabetic control group (p < 0.05).